Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: Ivermectin and COVID-19  Dec 13, 2020  3 years, 4 months, 4 days, 10 hours, 6 minutes ago

Yet Another Randomized Trial Shows Ivermectin Effectiveness To Treat COVID-19, This Time By Researchers From Clinica Universidad de Navarra-Spain

Yet Another Randomized Trial Shows Ivermectin Effectiveness To Treat COVID-19, This Time By Researchers From Clinica Universidad de Navarra-Spain
Source: Ivermectin and COVID-19  Dec 13, 2020  3 years, 4 months, 4 days, 10 hours, 6 minutes ago
Ivermectin to treat COVID-19 in various stages of the disease is turning to be a more viable and proven option despite strong opposition from groups with vested interest in America and Europe.\

This time, a double blind, placebo- controlled randomized clinical trial tested the efficacy of the drug to treat mild conditions of the disease and to see how it prevents high viral loads, how it prevented or reduced symptoms and how it helped the humoral reponse and also prevents disease progression etc. The results were positive and paved the way for larger trials to get Ivermectin to be accepted as a standard treatment protocol.
 
The study was conducted by reseachers from Clinica Universidad de Navarra-Spain, ISGlobal and Inselspital.
 
The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between the "la Caixa" Foundation, academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health. ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. 
 
The study findings were published on a preprint server and are currently being peer-reviewed. https://www.researchsquare.com/article/rs-116547/v1
 
The study team conducted a pilot, randomized, double-blind, placebo-controlled trial to determine the efficacy of a single dose of ivermectin to reduce the proportion of PCR positives, viral load at day 7 post treatment.
 
For the trial, participants were recruited from consecutive patients with confirmed SARS-CoV-2infection and mild COVID-19 (no pneumonia) and no risk factors for complicated disease attending the emergency room of the Clínica Universidad de Navarra. Patients were randomized 1:1 to receive ivermectin, 400 mcg/kg, single dose (n = 12) or placebo (n = 12).
 
The main primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7 post-treatment. The primary outcome was supported by determination of the viral load and infectivity of each sample.  The differences between ivermectin and placebo were calculated using Fisher’s exact test and presented as a relative risk ratio.
 
All COVID-19 patients recruited completed the trial (median age, 26 [range, 18-54] years; 12 [50%] women; 100% had symptoms at recruitment, 70% reported headache, 62% reported fever, 50% reported general malaise and 25% reported cough). At day 7, there was no difference in the proportion of PCR positive patients (RR 0.92, 95% CI: 0.77-1.09, p = 1.0).
 
The ivermectin group had lower median viral loads at days 4 and 7 post treatment as well as lower median IgG titers at day 21 post treatment. Hyposmia/anosmia (76 vs 158 patient-days) and cough (68 vs 97 patient-days) were less frequent in the ivermectin group.
 
Among patients with mild COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 48 h ours of fever or cough onset there was no difference in the proportion of PCR positives. There was however a marked reduction of anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.
 
The